A recent trial revealed promising results using traditional Qiliqiangxin, in the treatment of heart failure

A recent placebo-controlled trial presented at the European Society of Cardiology (ESC) 2023 Congress has revealed promising results regarding the use of a traditional Chinese herbal remedy, Qiliqiangxin, in the treatment of heart failure with reduced ejection fraction (HFrEF). HFrEF is a condition where the heart's left ventricle loses its ability to contract effectively, leading to insufficient blood circulation.

The study, known as QUEST, involved over 3,000 HFrEF patients who were randomly assigned to take Qiliqiangxin or a placebo in addition to their standard triple-therapy regimen for heart failure. Qiliqiangxin, composed of 11 plant-based ingredients known for their diuretic and cardiotonic effects, demonstrated a significant reduction in the risk of cardiovascular death and hospitalization due to heart failure by more than 20%. This reduction was consistent across various patient groups.

While these findings are promising, some questions remain, including the limited enrollment of patients taking other standard heart failure medications like SGLT-2 inhibitors. Nevertheless, the study suggests that Qiliqiangxin may offer a valuable addition to heart failure treatment options, particularly for patients who cannot tolerate certain components of standard therapy.

The capsules were well-tolerated with no major differences in adverse events between the Qiliqiangxin group and the placebo group. However, the regimen of four Qiliqiangxin capsules three times a day may pose challenges for some patients. Researchers also noted the need to further investigate the specific active ingredients in Qiliqiangxin and the standardization of herbal products.

In conclusion, this study offers hope for individuals with HFrEF and highlights the potential of traditional Chinese medicine in modern healthcare, though further research is needed to fully understand its benefits and mechanisms of action. Go to Medium Article

Comments

Exploring the Link Between Circadian Rhythms, Longevity, and Wearable Data: Insights and Future Directions

A recent study in NHANES 2011–2014 explores the potential connection between disruptions in circadian rhythms, measured using wearable devices, and their impact on health outcomes and longevity. The study analyzes data from 7,297 U.S. adults collected through wearable accelerometers as a novel digital biomarker for longevity. Five distinct clusters were identified based on activity profiles: "High activity," "Low activity," "Mild circadian rhythm (CR) disruption," "Severe CR disruption," and "Very low activity." The findings reveal that young adults with extreme circadian rhythm disturbance exhibit higher white blood cell counts and accelerated biological aging. Older adults with circadian disruption are associated with increased systemic inflammation indexes, advanced biological aging, and higher all-cause mortality risk. The research underscores the importance of circadian alignment for longevity at all ages and suggests that wearable

The safety of aspartame is under review by WHO after conflicting findings.

Aspartame, a sweetener with health effects Since 1981, the WHO expert committee on additives has confirmed the safety of aspartame consumption within acceptable daily limits. The international organization has established that the acceptable daily intake (ADI) of aspartame is 40 milligrams per kilogram of body weight. This means that a person can consume up to 40 mg of aspartame per kilogram of their body weight per day without risking their health. For example, if someone weighs 60 kilos, the allowable amount of aspartame would be 2,400 milligrams (40 mg/kg x 60 kg). In recent years, several studies have been carried out on the effects of aspartame on health. The Food and Drug Administration (FDA) has reviewed the scientific evidence related to the safety of this sweetener five times since its approval in 1981, and has concluded that it remains safe for use. However, it is being studied again. It has an especially important use in low-calorie beverages consumed by children and pregnan

Light Therapy holds promise as a treatment for Alzheimer's Disease

A new article, conducted by Lili Zang and colleagues from Weifang Medical University School of Nursing in Shandong Province, China, discusses a meta-analysis of 15 high-quality trials that investigated the impact of light therapy on individuals with Alzheimer’s disease (AD). The meta-analysis included 598 patients with mild to moderate Alzheimer’s disease, and it covered 15 randomized controlled trials conducted in seven different countries. Those trials were published between 2005 and 2022. Sleep Improvement Light therapy led to significant improvements in several sleep measures. It notably enhanced sleep efficiency, increased interdaily stability, and reduced intradaily variability, all of which are indicators of better sleep quality. Light therapy was associated with a reduction in agitation, depression, and caregiver burden among individuals with Alzheimer’s disease. A significant advantage over usual care was shown in reducing the severity of psychobehavioral symptoms, as assessed

Wellness-uptodate

Search This Blog